SCHEMBL2660635

SCHEMBL2660635

Brc1ccc2[nH]nc(Nc3nccs3)c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.58
FADS1 O60427 2/20 0.51
PDPK1 O15530 3/20 0.45
JAK2 O60674 2/20 0.45
DYRK1A Q13627 4/20 0.44
DCLK1 O15075 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
CHEK2 O96017 1/20 0.44
CSF1R P07333 1/20 0.44
FER P16591 1/20 0.44
CDK2 P24941 1/20 0.44
MARK3 P27448 1/20 0.44
FLT4 P35916 1/20 0.44
FLT3 P36888 1/20 0.44
MAPK9 P45984 1/20 0.44
CSNK1D P48730 1/20 0.44
CLK2 P49760 1/20 0.44
CSNK2A1 P68400 1/20 0.44
CSNK1G2 P78368 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660111 0.84 GRM4 (0.58) GRM4FADS1PDPK1JAK2MAPK1
SCHEMBL2667982 0.84 GRM4 (0.58) GRM4FADS1MAPK1NPC1RAB9A
SCHEMBL2660645 0.84 GRM4 (0.58) GRM4FADS1MAPK1
SCHEMBL2668091 0.82 GRM4 (0.55) GRM4FADS1PDPK1JAK2MAPK1
SCHEMBL2662181 0.81 GRM4 (0.54) GRM4MAPK1RIPK2
SCHEMBL2660583 0.81 GRM4 (0.54) GRM4FADS1MAPK1
SCHEMBL2662190 0.81 GRM4 (0.54) GRM4FADS1JAK2DYRK1AAURKB
SCHEMBL2654720 0.81 GRM4 (0.54) GRM4FADS1MAPK1MEN1NPC1
SCHEMBL2659835 0.81 GRM4 (0.54) GRM4FADS1CSF1RMAPK9CLK4
SCHEMBL2667991 0.79 GRM4 (0.52) GRM4FADS1JAK2MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 EP claimed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US claimed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 WO claimed
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 EP disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244169-A1 GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GRM4 1511/4885FADS1 1868/4885PDPK1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.